427 related articles for article (PubMed ID: 34868001)
21. Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation.
Iyengar S; Zhan C; Lu J; Korngold R; Schwartz DH
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1104-11. PubMed ID: 24796280
[TBL] [Abstract][Full Text] [Related]
22. The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Schroeder MA; Choi J; Staser K; DiPersio JF
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1125-1134. PubMed ID: 29289756
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
Schutt SD; Fu J; Nguyen H; Bastian D; Heinrichs J; Wu Y; Liu C; McDonald DG; Pidala J; Yu XZ
PLoS One; 2015; 10(9):e0137641. PubMed ID: 26348529
[TBL] [Abstract][Full Text] [Related]
24. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
Betts BC; Bastian D; Iamsawat S; Nguyen H; Heinrichs JL; Wu Y; Daenthanasanmak A; Veerapathran A; O'Mahony A; Walton K; Reff J; Horna P; Sagatys EM; Lee MC; Singer J; Chang YJ; Liu C; Pidala J; Anasetti C; Yu XZ
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1582-1587. PubMed ID: 29382747
[TBL] [Abstract][Full Text] [Related]
25. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S; Leigh ND; Cao X
Front Immunol; 2018; 9():3003. PubMed ID: 30627129
[TBL] [Abstract][Full Text] [Related]
26. Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT.
Mammadli M; Huang W; Harris R; Xiong H; Weeks S; May A; Gentile T; Henty-Ridilla J; Waickman AT; August A; Bah A; Karimi M
iScience; 2021 Apr; 24(4):102286. PubMed ID: 33851101
[TBL] [Abstract][Full Text] [Related]
27. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.
Zhao Y; Shi J; Luo Y; Gao F; Tan Y; Lai X; Yu J; Wei G; Huang H
Biol Blood Marrow Transplant; 2020 May; 26(5):e128-e133. PubMed ID: 31982545
[TBL] [Abstract][Full Text] [Related]
28. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Cetkovic-Cvrlje M; Uckun FM
Br J Haematol; 2004 Sep; 126(6):821-7. PubMed ID: 15352986
[TBL] [Abstract][Full Text] [Related]
29. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
30. B cells in chronic graft-versus-host disease.
McManigle W; Youssef A; Sarantopoulos S
Hum Immunol; 2019 Jun; 80(6):393-399. PubMed ID: 30849450
[TBL] [Abstract][Full Text] [Related]
31. Separation of GVL from GVHD -location, location, location.
Teshima T; Hashimoto D
Front Immunol; 2023; 14():1296663. PubMed ID: 38116007
[TBL] [Abstract][Full Text] [Related]
32. Ruxolitinib for the treatment of graft-versus-host disease.
Ali H; Salhotra A; Modi B; Nakamura R
Expert Rev Clin Immunol; 2020 Apr; 16(4):347-359. PubMed ID: 32153201
[No Abstract] [Full Text] [Related]
33. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
[TBL] [Abstract][Full Text] [Related]
34. Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans.
Norona J; Apostolova P; Schmidt D; Ihlemann R; Reischmann N; Taylor G; Köhler N; de Heer J; Heeg S; Andrieux G; Siranosian BA; Schmitt-Graeff A; Pfeifer D; Catalano A; Frew IJ; Proietti M; Grimbacher B; Bulashevska A; Bhatt AS; Brummer T; Clauditz T; Zabelina T; Kroeger N; Blazar BR; Boerries M; Ayuk F; Zeiser R
Blood; 2020 Sep; 136(12):1442-1455. PubMed ID: 32542357
[TBL] [Abstract][Full Text] [Related]
35. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
36. Resolution of acute intestinal graft-versus-host disease.
Thiagarajan S; Neurath MF; Hildner K
Semin Immunopathol; 2019 Nov; 41(6):655-664. PubMed ID: 31673757
[TBL] [Abstract][Full Text] [Related]
37. Murine Models Provide New Insights Into Pathogenesis of Chronic Graft-
Song Q; Kong X; Martin PJ; Zeng D
Front Immunol; 2021; 12():700857. PubMed ID: 34539630
[TBL] [Abstract][Full Text] [Related]
38. The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease.
Zeiser R; Socié G
Blood Adv; 2020 Aug; 4(15):3789-3794. PubMed ID: 32780849
[TBL] [Abstract][Full Text] [Related]
39. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
Martini DJ; Chen YB; DeFilipp Z
Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
[TBL] [Abstract][Full Text] [Related]
40. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.
Hülsdünker J; Ottmüller KJ; Neeff HP; Koyama M; Gao Z; Thomas OS; Follo M; Al-Ahmad A; Prinz G; Duquesne S; Dierbach H; Kirschnek S; Lämmermann T; Blaser MJ; Fife BT; Blazar BR; Beilhack A; Hill GR; Häcker G; Zeiser R
Blood; 2018 Apr; 131(16):1858-1869. PubMed ID: 29463561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
